The document calculates various financial metrics for AstraZeneca for the year 2013, including: - Economic Value Added (EVA) of $730.9 million, calculated as Net Operating Profit After Tax (NOPAT) of $3.016 billion minus a capital charge of $2.285 billion. - Return on Invested Capital of 9.53%, indicating the company is creating shareholder wealth. - Market Value Added (MVA) of $81.79 billion, calculated as the market value of the firm of $113.42 billion minus total invested capital of $31.634 billion.